Janssen's potential "first-in-class" dual-antibody therapy starts clinical trials in China

ArticleMedicine Guanlan

China's drug clinical trial registration and information disclosure platform shows that the Johnson & Johnson's Janssen's new class 1 drug, talentamab injection, has initiated a phase 2 treatment for relapsed or refractory multiple myeloma (MM) Clinical research

Screenshot source: Chinadrugtrials

GPRC5D (G protein coupled receptor C5 family subtype D) is an innovative multiple myeloma target, which is highly expressed in multiple myeloma cells and is associated with poor prognostic factors

According to the Chinese Drug Clinical Trial Registration and Information Disclosure Platform website, the launch in China this time is a project carried out in subjects with relapsed or refractory multiple myeloma, about the 1/2 phase of talentamab and its first use in humans.

It is worth mentioning that at the 2020 American Society of Hematology (ASH) annual meeting, Janssen Company has announced the results of early clinical trials of valvetamab in the treatment of multiple myeloma patients.

At the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Janssen once again announced the follow-up data of the first phase 1 human dose escalation study (MonumenTAL-1) of talentamab

These efficacy and safety data indicate that talentamab is a promising treatment candidate for patients with multiple myeloma who have relapsed after multiple treatments or have not responded to other treatments

Reference materials:

[1] Drug clinical trial registration and information disclosure platform.

[3] Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma.